Biologic Principles of Immunotherapy for Malignant Gliomas

Seunggu J. Han, BS[a], Gurvinder Kaur, BS[a],
Isaac Yang, MD[a],*, Michael Lim, MD[b]

KEYWORDS
- Immunotherapy • Glioma • Tumor-specific antigen
- Immunosuppression

The most common primary brain neoplasm is glioblastoma multiforme (GBM), which is associated with a dismal prognosis. Despite the recommended treatment regimen of aggressive surgical resection, radiation, and chemotherapy, the median survival remains approximately only 14 months.[1] Due to these minimal improvements in survival of patients despite recent advances in conventional treatments, new modalities such as immunotherapy are being investigated and studied.[2] In this article the current strategies and principles of immunotherapy for gliomas is described.

The central nervous system (CNS) historically has been considered an immune-privileged organ where immune activity is significantly silenced.[3] Several unique anatomic and physiologic characteristics limit immune surveillance and response functions in the brain,[4] such as: (1) the CNS lacks a lymphatic system; (2) the brain is shielded from the peripheral circulatory system by the blood-brain barrier (BBB), and thus is isolated from most peripheral immune cells, soluble factors, and plasma proteins; (3) the high levels of immunoregulatory cells and factors in the brain further mute immune functions; and (4) cells of the CNS at baseline express very low levels of major histocompatibility complex (MHC) molecules responsible for antigen presentation to immune effector cells.[5,6]

However, despite these factors minimizing CNS immune function, a highly adapted system of immune surveillance exists, and effective immune responses can occur in the CNS. Activity of both the complement system[7] and the antigen-antibody system, including functional B cells,[8,9] have been found within the CNS. During CNS insults, resident antigen-presenting cells (APC) of the CNS, microglia cells, undergo activation and upregulate both MHC and costimulatory molecules, and also contribute to both CD4+ and CD8+ specific T-cell responses.[10–12] A small number of lymphocytes are found in normal, healthy brain,[13] but both naïve lymphocytes[14] and activated T cells have the ability to cross the BBB.[13,15,16] Many different types of lymphocytes also infiltrate the CNS in the presence of a variety of CNS pathologies, including glioma.[17–20] However, the magnitude and potency of these immune responses in the CNS still remains to be clearly elucidated.[16]

TUMOR-ASSOCIATED IMMUNOSUPPRESSION

Malignant brain tumors such as gliomas display an ability to evade and suppress the immune system.[21] Gliomas can evade the immune system at different levels of antigen recognition and immune activation.[22] First, by limiting effective signaling between glioma and immune cells, glioma cells evade immune detection. Many glioma cells express low levels of human leukocyte antigens (HLA) or express defective HLA.[6] A recent report by Facoetti and colleagues[23] described approximately 50% of 47 glioma

[a] Department of Neurological Surgery, University of California at San Francisco, 505 Parnassus Avenue, San Francisco, CA 94117, USA
[b] Department of Neurological Surgery, Johns Hopkins University School of Medicine, Phipps Building, Room 123, 600 N. Wolfe Street, Baltimore, MD 21287, USA
* Corresponding author.
E-mail address: yangi@neurosurg.ucsf.edu (I. Yang).

samples displayed loss of the HLA type I antigen. Among these, 80% showed evidence of selective loss of HLA-A2 antigen. Of note, loss of HLA type I antigen was more common among higher grade tumors, suggesting a role of deficient antigen presentation in glioma progression.

Inhibition of antigen presentation by microglia and macrophages in the tumor microenvironment also contributes to the tumors' ability to escape immune detection. In vitro, the presence of glioma cells induces monocytes to reduce their phagocytic activity.[24] In addition, microglia found within glioma tissue appear to be deficient in proper antigen presentation for cytotoxic and helper T-cell activation.[25] Schartner and colleagues[26] demonstrated that MHC-II induction by stimulation was significantly less in microglia and infiltrating macrophages derived from gliomas than in those isolated from normal brain. The mechanism for this defective MHC-II response in tumor-associated microglia and macrophages remains unclear in regard to whether they result from a local immunosuppressive milieu, impaired signaling, or another unique inherent phenotype of tumor-associated microglia and macrophages. Stimulation of microglia in the presence of tumor cells reduces the secretion of proinflammatory cytokines, such as tumor necrosis factor (TNF)-α, but also increases the secretion of the inhibitory cytokine interleukin (IL)-10.[27]

In the presence of glioma, T cells, specifically the CD4+ population, both in peripheral blood and in the tumor microenvironment, have depressed function.[28,29] Innate helper T cells (CD4+) display weak proliferative responses and dramatically lowered synthesis of the T_H1 cytokine IL-2.[30]

The degree of infiltrating lymphocytes found within gliomas has been found to correlate with patient survival.[31–33] However, other studies have failed to reproduce this finding.[34] Despite the presence of large numbers of glioma-infiltrating lymphocytes, the function and activity of these lymphocytes is difficult to predict. In fact, Hussain and Heimberger[35] demonstrated that the vast majority of CD8+ T cells found within gliomas are not activated. One hypothesis states that these are actually naïve T cells passively infiltrating the tumor across a compromised BBB caused by the tumor; alternatively, they may represent a population that once was active but has been subsequently rendered inactive by the host of immunosuppressive mechanisms found in the tumor microenvironment.

In patients with malignant glioma, a subpopulation of T lymphocytes termed T-regulatory cells (CD4+CD25+ cells; T_{regs}), which suppresses activity of effector T cells, is increased.[23,26,36–38] By downregulating the production of key cytokines, such as IL-2[39] and interferon (IFN)-γ[40,41] from target lymphocytes, they potently inhibit T-cell activation, proliferation, and differentiation.[39] T_{regs} also induce lymphocytes to secrete predominantly T_H2 cytokines, such as IL-10,[42] and TGF-$\beta2$,[43] which in turn continues to propagate the regulatory phenotypes of T lymphocytes.[44] In vivo experiments have demonstrated significantly improved survival after depleting T_{regs} in brains of mice harboring GL261 gliomas by injecting an antibody targeting against T_{regs} (anti-CD25+ mAb).[45,46]

Secretion of various immune inhibitory cytokines and molecules by glioma cells also plays a large role in glioma-associated immunosuppression. IL-10 is also selectively secreted by invasive glioma.[47] Malignant glioma cells produces large amounts of prostaglandin E2,[48,49] which in turn inhibits IL-2 activation of lymphocytes.[50,51] High levels of expression of TGF-$\beta2$ are present in malignant glioma.[50,52] TGF-$\beta2$ mRNA is present in samples of human glioblastoma but not in normal adult brain.[52] TGF-$\beta2$ has previously been referred to as glioblastoma cell-derived T-cell suppressor factor (G-TsF) because of its potent immunosuppressive activity,[53] particularly in inhibition of cytotoxic T cells.[54,55] In addition, inhibition of signaling through the TGF-$\beta2$ pathway by antisense RNA in the C6 rat glioma model significantly prolonged survival,[56] and at times eradicated the tumor entirely.[57] These experiments are strongly supportive of the key role TGF-$\beta2$ plays in the immunosuppression that seems essential for the survival of glioblastoma cells.

In addition to the secreted immunosuppressive factors, expression of molecules that induce apoptosis of immune effectors, such as Fas ligand, galectin-1, and B7-H1, contribute to the immunosuppressive activity of gliomas.[58,59] Fas ligand (FasL, CD95L) and its receptor Fas (CD95) are important mediators of apoptosis in the immune system, particularly of CD8+ cytotoxic lymphocytes. High expression of FasL by human glioma cells naturally has been found to be associated with low levels of T-cell infiltration,[60] suggesting that FasL expression by tumor cells may contribute to T-cell depletion in tumors by increased T-cell apoptosis. However, the clinical significance of levels of FasL expression remains to be determined. Galectin-1 induces apoptosis in a variety of immune cell types through an alternative signaling pathway from Fas/FasL.[61] Overexpression of galectin-1 by gliomas likely also contributes to increased apoptosis of T cells by gliomas, serving as another method of evasion from antitumor activity of T lymphocytes. Higher

levels of expression of galectin are found in higher grade astrocytomas.[62] B7-H1 is a potent immunosuppressive surface molecule that induces T-cell apoptosis by the PD-1 signaling pathway. A subset of gliomas with particularly strong immunoresistant phenotypes has high levels of B7-H1 expression on the surface.[59] In addition to the expression of apoptotic molecules targeted at T lymphocytes on glioma cells, microglia in presence of glioma have elevated levels of FasL and B7-H1.[63–65]

Iatrogenic factors may cause a systemic immunosuppression in patients with glioma. Corticosteroids given for tumor-associated edema may cause inhibition of cytokine production and sequestration of CD4+ T cells.[66] Recent evidence suggests, however, that at therapeutic doses corticosteroids may not interfere with immunotherapy.[67] Chemotherapeutic agents, such as temozolomide, for example, can cause lymphopenia, particularly of the CD4+ population,[68] which may compound immunotherapeutic modalities that depend on CD4+ T cell response. Other agents such as rapamycin inhibit production of the proliferative cytokine IL-2.[66]

IMMUNOTHERAPY

Challenges in management of malignant gliomas have been rooted in inevitable recurrences of the tumor despite aggressive therapy. This challenge highlights the diffusely infiltrative nature of the tumor with evidence of microscopic disease that has already spread diffusely beyond the tumor mass at the time of clinical presentation.

The development of a successful mode of therapy requires systemic efficacy throughout the brain, with the ability to target tumor cells left behind after surgical resection and conventional adjuvant therapies. Such systemic therapy must also be highly specific for infiltrating tumor cells. Immunotherapy represents an attractive modality, with the potential to harness the potency, specificity, and memory of the immune system against infiltrating glioma cells.

Strategies in antiglioma immunotherapy broadly include cytokine therapy, passive immunotherapy, and active immunotherapy. Cytokine therapy is based on the concept that administration of immunomodulatory cytokines will activate the immune system. Passive immunotherapy includes serotherapy, in which monoclonal antibodies are given to aid immune recognition of tumor and deliver toxins to tumor cells, and adoptive therapy, which involves tumor-specific immune cells that are expanded ex vivo and reintroduced to the patient. Active immunotherapy involves generating or augmenting the patient's own immune response to tumor antigens, typically by administering tumor antigens or professional APCs.

Cytokine Therapy

Cytokines have a potent capacity for immunomodulation, and immunotherapy with cytokines has been applied in oncology against a variety of tumors with variable success. In vitro experiments have established the efficacy of cytokines in eliciting antitumor activity of immune effector cells.[69] Different strategies for delivery of cytokines to the CNS have been explored, including injection/infusion of recombinant cytokines, vectors containing cytokine encoding genes, cells that secrete cytokines, or cytokines linked to toxins.

The first clinical trial using cytokine immunotherapy employed intratumoral IFN-α in addition to surgery and radiotherapy, and compared the trial group with a group who received surgical resection, radiation, and chemotherapy.[70] Although the investigators reported encouraging results, conclusions drawn regarding efficacy of IFN-α were limited due to flaws in study design.[21] Farkkila and colleagues[71] published the results of their trial using IFN-γ neoadjuvant and adjuvant to radiotherapy. Although the therapeutic regimen was well tolerated, there was no statistically significant difference in overall survival between the trial and control groups.[71] Studies that followed using systemic or intrathecal administration of IFN-α, IFN-γ, or IL-2 continued to find no significant improvement in survival while patients in the treatment arm encountered considerable toxicities.[72–74] Current approaches are looking to targeted delivery of cytokines to reduce systemic toxicity and increase the effective cytokine concentrations within the tumor.

Viral vectors have been used for local delivery of cytokines, with evidence of glioma-specific responses.[75–77] Strategies using intratumoral implantation of various cell types genetically modified to produce cytokines have produced more encouraging results. Injection of IL-2–secreting allogeneic fibroblasts into GL261 tumors in mice significantly delayed tumor development when injected before the tumor cells, and prolonged survival in mice with established tumors.[78–80] Neural stem/progenitor cells have many qualities that make them attractive candidates for carriers for delivery of cytokines. These cells self replicate, have prolonged survival, and migrate further than do viral vectors. Injection of neural stem/progenitor cells transfected to produce IL-2,[81] IL-4,[82]

IL-12,[83] and IL-23[84] into animals with established gliomas improved survival.

Alternative vehicles for intratumoral injection include liposomes and biopolymer microspheres. Injection of liposomes containing a plasmid with the IFN-β gene into GL261 gliomas in mice induced a robust activation of natural killer cells,[85] IFN-β expression by tumor cells, significant infiltration of cytotoxic T cells, a 16-fold reduction in mean tumor volume, and a complete response in 40% of animals.[86] These effects were much more robust than those seen with exogenous administration of IFN-β.[86] These infiltrative T cells as well as systemic T cells were isolated from treated mice, and were shown to have specific antitumor responses.[87] Biopolymer microspheres containing IL-2 are also effective in generating a specific response when injected into tumors of mice[88,89] and rats.[90]

Cytokines have also been used to deliver toxins such as *Pseudomonas* exotoxin. Malignant glioma cells[91,92] and medulloblastoma cells[93] express high levels of the IL-4 receptor (IL-4R) on their surface not found on normal brain cells. This overexpression has been used for selective delivery of toxins. Cytotoxic effects of *Pseudomonas* exotoxin conjugated to IL-4 against glioma and medulloblastoma cells have been demonstrated in culture.[92,93] In a clinical trial of intratumoral injection of IL-4–pseudomonas exotoxin for patients with high-grade glioma, 6 of 9 patients enrolled showed evidence of tumor necrosis, and there was no significant toxicity found in any patient.[94] Current clinical trials are continuing to evaluate this modality's efficacy and maximum tolerated dose.[95,96]

IL-13R is similarly overexpressed in malignant glioma, but not in normal brain cells.[97–99] IL-13 conjugated to *Pseudomonas* exotoxin also is well tolerated when given intratumorally for patients with recurrent, malignant glioma.[100–102] Recent efforts have focused on optimizing the specificity and strength of the interaction between IL-13 and IL-13R of glioma cells,[103] as well as novel modes of delivery of the interleukin-toxin.[104] *Pseudomonas* exotoxin conjugated to TGF-α has also resulted in improvement in survival of mice bearing tumor xenografts, with greater improvements seen in mice that express the epidermal growth factor receptor (EGFR).[105,106] In a phase 1 trial, 2 patients received intratumoral infusions of TGF-α conjugated to the *Pseudomonas* exotoxin, and showed radiographic response with relative safety.[107]

Overall, immunotherapy with cytokines has demonstrated relative safety, with variable efficacy. Thus, given the relative nonspecificity of cytokine therapy, it may ultimately prove most useful as an adjunct to other types of therapies, and potential use of cytokines as adjunct to chemotherapy, termed chemoimmunotherapy, is an active area of development.[90,108]

Passive Immunotherapy

Serotherapy

Passive immunotherapy includes serotherapy and adoptive immunotherapy. Serotherapy uses monoclonal antibodies to effect an antitumor response or to achieve very specific delivery of toxins, chemotherapy, or radiotherapy to the tumor cells. An important determinant of its success is the identification of "tumor antigens," specific antigens expressed on tumor cell surfaces but not on normal brain parenchyma. In human gliomas, antigens of interest have been those with quantitative differences between glioma and normal cells. Targeted glioma antigens have included tenascin, EGFR and its mutated form EGFRvIII, chondroitin sulfate, vascular endothelial growth factor (VEGF) receptor, neural cell adhesion molecule (NCAM),[109] and hepatocyte growth factor/scatter factor.[110]

Tenascin is an extracellular matrix protein that is strongly expressed in gliomas but not in normal brain. Tenascin is readily identified immunohistochemically by monoclonal antibody (mAb) 81C6.[111] Systemic administration of ^{131}I-conjugated 81C6 mAb to mice with human glioblastoma xenografts prolonged survival,[112,113] with evidence of localization of the radioisotope to the tumor.[114] Clinical trials of ^{131}I-conjugated 81C6 mAb given intrathecally have shown relative safety of the technique at low radiation doses, with dose-limiting neurotoxicity and hematologic toxicity at higher dose.[115–117] Several phase 1 and 2 trials studying ^{131}I-conjugated 81C6 mAb injected into the surgical resection cavity in humans with glioblastoma have shown improved survival in patients with malignant gliomas relative to those receiving traditional therapies.[115,118–123]

Similar to tenascin, EGFR is specifically overexpressed by glioma cells, and signaling through EGFR is believed to play a key role in survival, proliferation, and progression of gliomas. In a clinical trial by Kalofonos and colleagues,[124] patients with high-grade gliomas with evidence of localization of markers linked to anti-EGFR mAb to tumor radiographically were treated with ^{131}I-conjugated mAb to EGFR injected intravenously or infused into the internal carotid artery.[125] Six of 10 treated patients showed clinical response lasting 6 months to 3 years, with no major toxicity.[125] In another trial, increasing doses of murine anti-EGFR mAb, EMD55900 (mAb 425) was given in

a single intravenous injection to 30 patients with malignant gliomas.[126] In 73% of patients, there was evidence of significant binding of EMD55900 to the tumor.[126] Similar binding was observed by Crombet and colleagues.[127] In a phase 1/2 study in which patients were given repeated infusions of EMD55900, toxicity was minimal, but no significant therapeutic benefit was found, as 46% of patients had progressed at 3 months.[128] Yet another trial using EMD55900 was stopped due to high levels of toxicity of inflammatory reactions.[129] Another phase 1/2 trial used a humanized anti-EGFR antibody, h-R3, designed to inhibit the kinase activity of the receptor for patients with malignant glioma, and demonstrated no high-grade toxicity and overall 37.9% response rate with stable disease in 41.4% patients at median follow-up of 29 months.[130] Several other phase 1, 2, and 3 trials have been conducted using EMD55900 conjugated to ^{125}I.[131–134] These trials have demonstrated that the conjugated mAb effectively localizes to the GBM and is well tolerated. A phase 2 trial in which patients received radiolabeled mAb following standard surgical resection and radiation therapy demonstrated a median survival of 15.6 months.[133] A similar study reported median survival of 13.5 months.[134] Phase 3 trials are currently ongoing.[131]

EGFRvIII is a constitutively active mutant form of EGFR, and as a tumor antigen that likely has a large role in tumorigenicity, is an attractive target for serotherapy.[135] Y10, a mAb developed against a murine homologue of EGFRvIII, can generate antibody-dependent cell-mediated cytotoxicity in vitro.[136] In vivo, a single dose of Y10, injected intratumorally into an intracranial murine B16 melanoma transfected to produce EGFRvIII, prolonged survival by 286%.[136] This mechanism of this effect was Fc receptor-dependent.[136] Systemic injections of the anti-EGFRvIII mAb 806 into mice with U87 glioma xenografts significantly reduced tumor volume and increased survival.[137]

Antibodies can provide specific targeted delivery of chemotherapeutics or toxins as well. Mamot and colleagues[138] used fragments of mAbs binding both EGFR and EGFRvIII conjugated to immunoliposomes containing the cytotoxic drugs doxorubicin, vinorelbine, and methotrexate, and observed delivery of these drugs to glioblastoma cells in vitro. These investigators observed intracellular accumulation in glioma cells of the drug at high rates, beginning at 15 minutes.[138] The toxicity to the tumor cells was also higher when immunoliposomal formulation was given, compared with the same drugs given without the liposomes.[138] The same group followed this study with experiments in xenograft models, showing superior efficacy in slowing tumor growth of EGFR-targeted immunoliposomes containing cetuximab.[139] Antibodies have also been conjugated to several different toxins, with varying results.[140] The specificity of delivery of therapeutic agents by mAb to tumor-specific antigens holds great potential for limiting therapeutic toxicity in immunotherapy against gliomas.

Adoptive immunotherapy

Adoptive immunotherapy augments the antitumor response with the reintroduction of immune effector cells that have been isolated from patients and expanded ex vivo. Expansion of cells ex vivo permits amplification under controlled conditions isolated from the immunosuppressive tumor microenvironment. Most adoptive immunotherapeutic strategies have used harvested lymphocytes stimulated with IL-2, without the presence of specific antigens. This process creates lymphokine-activated killer cells (LAKs). Others have used tumor-infiltrating lymphocytes, neural stem cells (discussed earlier), tumor-draining lymph node T cells, and non-MHC-restricted, cytotoxic T-cell leukemic cell lines.

Jacobs and colleagues[141] reported the first clinical trial studying immunotherapy with LAKs. LAKs and IL-2 were infused directly into the tumor bed of patients with malignant glioma, with minimal toxicity,[142] and mean progression-free survival in this small cohort was 25 weeks.[143]

Other trials using this technique found a small benefit in patient survival, but demonstrated dose-limiting neural toxicity related to cerebral edema, due to IL-2.[144–146] A recent study by Dillman and colleagues[147] reported a median survival of 17.5 months in glioblastoma patients who had LAKs placed in the resection cavity compared with 13.6 months in controls. In mouse models, LAKs coated with a bispecific anti-CD3 and anti-glioma antibodies increased the LAK activity of peripheral blood lymphocytes against the xenograft gliomas.[148] The application of these coated LAKs in clinical trials showed promising results. Infusion of coated LAKs into the tumor bed in human malignant gliomas resulted in either partial or complete regression tumor radiographically in 8 of 10 patients.[149] None of the 10 patients suffered tumor recurrence during the 10- to 18-month follow-up, and 9 of the 10 control patients given untreated LAK cells developed a recurrent tumor within 1 year.[149]

Tumor-infiltrating lymphocytes (TILs) found within glioma tissue contain a higher proportion of cytotoxic (CD8+) T cells compared with the composition of the peripheral blood lymphocyte population. Presuming their recognition and activity to

one or more tumor antigens, combined with the fact that they are readily expanded in culture, has made TILs potential candidates for adoptive immunotherapy. In vitro, when compared with LAKs, TILs are much more cytotoxic to glioma cells.[150]

Saris and colleagues[151] studied the antitumor activity of these TILs in a murine glioma model (GL261). TILs were incubated with enzymatically digested GL261 cells and IL-2, and then infused intraperitoneally into mice harboring gliomas in the liver or brain. The infusion reduced the number of liver metastases relative to that in animals receiving saline or IL-2 alone, but did not lengthen the survival of animals with GL261 tumors in the brain, leading the investigators to conclude that the inefficacy of TIL therapy in the brain reflects the unique challenges of the immunosuppressive tumor microenvironment, and that more efficient delivery systems need to be evaluated.[151] Subsequent studies, however, have reported success with TIL in treatment of intracranial gliomas in vitro.[152,153] Several clinical pilot studies have described the feasibility of reinfusion of IL-2 and autologous TILs expanded in vitro to patients systemically and locally, with little toxicity.[154,155] Evidence for efficacy of such technique is currently lacking. However, TILs display many dysfunctional functions that contribute to the failure to generate an effective antitumor response in vivo: altered cellular signaling, decreased proliferation, defective cytokine secretion, decreased cytotoxic capacity, and a predisposition toward apoptosis.[49,156–159] Despite their defects, the superior specificity of TILs over LAKs and early clinical success with TIL strategies warrant further investigation.

Plautz and colleagues[160] employed a novel technique using the site of tumor-rich vaccine injection. In a phase 1 clinical trial, 12 patients with astrocytoma, anaplastic glioma, or GBM were initially were given these T lymphocytes from injection site–draining lymph nodes after activation and expansion ex vivo.[161] Partial regression was observed in 4 patients, and no long-term toxicity was seen during the 2-year follow-up period.[161]

The use of MHC nonrestricted, cytotoxic T-cell lines has also been explored. TALL-104, one such clone, was established from a patient with acute T-lymphoblastic leukemia, and is able to distinguish between tumor and normal cells with MHC nonrestricted tumoricidal activity. Transfer of TALL-104 cells into tumor sites of U87 xenografts in mice significantly reduced tumor growth[162] and prolonged survival,[163] by the dual mechanisms of direct tumoricidal action and recruitment of endogenous antitumor activity.[164]

Geoerger and colleagues[165] subsequently showed evidence of significant cytotoxic activity of TALL-104 cells against several human glioblastoma and medulloblastoma cell lines in rat models, and stressed the importance of local, as opposed to systemic, administration of TALL-104 cells. Preclinical studies have characterized the cytotoxic activity, trafficking patterns, viability of TALL-104 cells under different conditions, and activity against brain tumor versus normal brain cells have concluded that TALL-104 cells are appropriate for human clinical trials.[166,167] TALL-104 implantation therapy shows killing of glioma cells, but not of normal brain cells, through a mechanism mediated by specific cytokine release, and their activity is not altered by presence of radiotherapy or corticosteroids.[166] Recent studies have further elucidated the wide array of mechanisms of cytotoxic activity against tumor cells by TALL-104 cells.[168]

Unfortunately, expression of tumor antigens, such as EGFRvIII, is not uniform among cells of a given tumor.[169] Thus, adoptive immunotherapy targeting a single tumor-specific antigen can be compounded by variants in the target, allowing evasion from immune-mediated killing. This lack of efficacy has been seen with adoptive T cell therapy directed at melanoma-specific antigens, with the result of preferential survival of tumors with antigenic variants.[170] Therefore, it is likely that the most successful adoptive cell transfer therapies will target multiple tumor antigens. Adoptive immunotherapy, like cytokine therapy, although not fully effective by itself, may become an important adjuvant to standard treatments and other immunotherapies for primary brain tumors.

Active Immunotherapy

Active immunotherapy involves priming or augmenting patients' immunity in vivo by vaccination against tumor antigen. Tumor vaccines for malignant glioma have been the focus of great interest in recent years. Successful development of glioma vaccines, however, requires proper presentation of tumor antigens and induction of effective, durable antigen-specific T cell immune response. Early efforts in active immunotherapy used vaccines containing autologous tumor cells as a source of tumor antigens, given with various cytokines for immune stimulation.[171–174] Despite evidence of safety and feasibility of such techniques, challenges remain due to innate poor antigen-presenting capacity of tumor cells, with low levels of expressed costimulatory molecules.

To augment the process of antigen presentation, professional APCs have also been used in glioma vaccines. Recent interest has turned to dendritic cells (DCs), which have an abundant expression of costimulatory molecules and have great capacity for activating T lymphocytes. DCs are exposed to tumor antigens, then used to initiate an antitumor response in the patient's endogenous T cells.[175] More specifically, autologous DCs are obtained from peripheral blood mononuclear cells or bone marrow, primed to maturation, exposed to whole tumor cell lysate or tumor antigen ex vivo, and reintroduced to the patient. In vitro experiments have established the ability of DCs exposed to tumor antigens in inducing T cell proliferation and generating cytotoxic responses.[176,177]

In clinical trials, DCs have been exposed to tumor antigens in a variety of ways, including whole tumor cells, isolated peptides, tumor lysates, or tumor RNA. An early phase 1 trial used peptide-pulsed DCs isolated from peripheral blood and showed the generation of robust T cell infiltration into the tumor.[178] Early efforts by Kikuchi and colleagues[179] employed DCs fused to glioma cells and injected intradermally for patients with malignant gliomas. No adverse reactions, but a partial response in only 2 of 8 patients, was observed.[179] In a subsequent study by these investigators, IL-12 was added to the formulation and more robust response was seen: there was a 50% radiographic reduction of the tumor in 4 of 15 patients, with similar safety profiles.[180] A complete regression of glioma was achieved in the murine GL261 model when a regimen of intrasplenic vaccination with DC/tumor fused cells, local cranial radiotherapy, and anti-CD134 mAb 7 was given.[181] Other strategies of DC exposure to antigens have involved using tumor lysates.[182,183] Reintroduction of DCs preloaded with total tumor RNA rather than tumor antigen also produced a strong cytotoxic T cell response against autologous glioma cells.[183] These early clinical trials have yielded encouraging results regarding generating responses and improving survival in patients.[179,183–185] Liau and colleagues[185] proposed that the most promising patient subgroup for DC vaccine therapy may be patients with small, quiescent tumors with low expression of tumor TGF-β. The phase 2 randomized trial using tumor lysate pulsed DC vaccine is ongoing.

The use of unselected tumor extracts to prime DCs in such nonspecific approaches risks inducing autoimmunity against antigens of normal brain.[186] In efforts to avoid this potential hazard, focus has turned to more specific approaches using tumor-specific antigens, such as EGFRvIII as targets for glioma vaccines. Preliminary studies using EGFRvIII peptide-pulsed DCs showed generation of cytotoxic activity against the U87 human glioma cell line.[187] When the same vaccine was given to mice that subsequently received intracerebral injections of syngeneic melanoma expressing the murine homologue of EGFRvIII, animals that were immunized survived 6 times as long as those that were not immunized.[188] Among immunized mice, 63% survived long term and 100% survived rechallenge with melanoma, indicating evidence of immunologic memory against the tumor.[188]

A peptide-based vaccine targeting the tumor-specific mutated portion of EGFRvIII is also under investigation. A phase 1 trial with enrollment of 19 patients has been completed. The therapy was shown to be well tolerated, and treated patients had progression-free survival of 12 months and median overall survival of 18 months.[189] Of note, recurrent tumors after the vaccine showed no expression of EGFRvIII.[189] The phase 2/3 randomized trial of the EGFRvIII peptide vaccine with radiation and temozolomide is currently ongoing.

Another peptide-based vaccine currently under study is based on heat-shock protein gp96 and its associated peptides isolated from the patient's autologous tumor acquired at time of surgery. Preliminary results of the ongoing phase 1/2 trial have demonstrated the vaccine to be well tolerated, with evidence of induction of tumor-specific responses.

Alternative active immunotherapeutic approaches have aimed at initiating an immune response to tumor in vivo through lymphocytes. In one such study, peripheral lymphocytes removed from patients with high-grade gliomas were cultured with irradiated tumor cells in the presence of bacillus Calmette-Guérin and IL-2, then systemically reinfused into patients, with minimal toxicity.[190] Two of 9 patients experienced increased survival with evidence of tumor regression, 1 had tumor regression but not increased survival, and the remaining 6 had neither.[190]

Infectious agents have also been used to induce an antigen-specific immune response to gliomas. These vaccines contain viral or bacterial vectors carrying tumor antigen genes, and the concept involves that an immune response to the highly immunogenic infectious agent should augment the response to the tumor antigen as well. Such an approach in animal models using *Listeria monocytogenes* have shown efficacy against extracranial but not intracranial tumor, suggesting potential for improved efficacy in gliomas with improved delivery systems to the CNS.[191,192] In a phase 1 trial, recombinantly modified vaccinia virus Ankara carrying the cDNA for a melanoma

antigen has proven safe, and capable of eliciting a strong response against the virus but not against the antigen.[193]

MULTIMODALITY IMMUNOTHERAPY

Cytokine and active immunotherapy strategies have been combined by introducing tumor cells or fibroblasts transfected to produce cytokines, such as IL-2, IL-4, IL-12, IL-18, IFN-α and granulocyte macrophage colony stimulating factor (GM-CSF) alone or in combination with DCs.[17,194–197] Several studies suggest the promise of this strategy. Intratumoral administration of IL-2–producing tumor cells along with recombinant IL-12 significantly prolonged survival in mice.[198] Tumor cells producing GM-CSF or B7-2, a costimulatory molecule, when injected locally to the tumor, also increased survival in mice.[199] In rat models, when cDNA of IFN-γ,[200] TNF-α,[77] and IL-4[201] were delivered retrovirally to glioma cells in situ, a strong immune response was generated and complete elimination of established tumors was seen.

SUMMARY

The continued poor prognosis of patients with gliomas, despite current treatment protocols, warrants new therapeutic approaches. Advance stage clinical trials of several promising immunotherapies are currently ongoing, and their results will determine the clinical value of these modalities. Challenges to immunotherapy remain numerous. Although immunotherapy and chemotherapy can potentially serve as coadjuvants, the current practice of administering temozolomide during and 6 months after radiation therapy is an impediment to clinical testing of immunotherapies, which may be compromised both by concurrent chemotherapy and immunosuppression that accrues with time.

Another large hurdle in developing effective immunotherapy is the immunosuppressive characteristics that are the hallmark of malignant gliomas. Effective therapeutic strategies will require overcoming these mechanisms, by augmenting tumor antigen presentation, perhaps in a setting isolated from the tumor microenvironment. The heterogeneity of potential glioma antigens warrants targeting of multiple tumor-specific antigens, and discovery and investigation of additional antigens. The optimal immunotherapy will likely employ several of the strategies reviewed here and will become a standard component of a combined multimodal approach to malignant gliomas.

REFERENCES

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10):987–96.
2. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 2004;10:887–92.
3. Medawar P. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948;29(1):58–69.
4. Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier, and the immunoreactivity of the brain. In: Keane RW, Hickey WF, editors. Immunology of the nervous system. New York: Oxford University Press; 1997. p. 134–52.
5. Lampson L, Hickey WF. Monoclonal antibody analysis of MHC expression in human brain biopsies. Tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 1986;136:4052–62.
6. Yang I, Kremen TJ, Giovannone AJ, et al. Modulation of major histocompatibility complex class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 2004;100(2):310–9.
7. Levi-Strauss M, Mallat M. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol 1987;139:2361–6.
8. Bernheimer H, Lassmann H, Suchanek G. Dynamics of IgG+, IgA+, and IgM+ plasma cells in the central nervous system of guinea pigs with chronic relapsing experimental allergic encephalomyelitis. Neuropathol Appl Neurobiol 1988;14:157–67.
9. Sandberg-Wollheim M, Zweiman B, Levinson AI, et al. Humoral immune responses within the human central nervous system following systemic immunization. J Neuroimmunol 1986;11(3):205–14.
10. Aloisi F, Ria F, Columba-Cabezas S, et al. Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1/Th2 cell restimulation. Eur J Immunol 1999; 29(9):2705–14.
11. Aloisi F, Ria F, Penna G, et al. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol 1998;160(10):4671–80.
12. Brannan CA, Roberts MR. Resident microglia from adult mice are refractory to nitric oxide-inducing stimuli due to impaired NOS2 gene expression. Glia 2004;48(2):120–31.

13. Hickey WF, Kimura H. Graft-vs-host disease elicits expression of class I and class II histocompatibility antigens and the presence of scattered T lymphocytes in rat central nervous system. Proc Natl Acad Sci U S A 1987;84(7):2082–6.

14. Krakowski M, Owens T. Naive T lymphocytes traffic to inflamed central nervous system, but require antigen recognition for activation. Eur J Immunol 2000;60:5731–9.

15. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991;28(2):254–60.

16. Hickey WF. Basic principles of immunological surveillance of the normal central nervous system. Glia 2001;36(2):118–24.

17. Sampson J, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 1996;93(19):10399–404.

18. Gordon LB, Nolan SC, Cserr HF, et al. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J Immunol 1997;159(5): 2399–408.

19. Badie B, Schartner JM, Paul J, et al. Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 2000;93(4):634–9.

20. Sawamura Y, Hosokawa M, Kuppner MC, et al. Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res 1989;49(7):1843–9.

21. Das S, Raizer JJ, Muro K. Immunotherapeutic treatment strategies for primary brain tumors. Curr Treat Options Oncol 2008;9(1):32–40.

22. Parney I, Hao C, Petruk K. Glioma immunology and immunotherapy. Neurosurgery 2000;46(4):778–91.

23. Facoetti A, Nano R, Zelini P, et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 2005;11(23):8304–11.

24. Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg 2009;110(3):572–82.

25. Flugel A, Labeur MS, Grasbon-Frodi EM, et al. Microglia only weakly present glioma antigen to cytotoxic T cells. Int J Dev Neurosci 1999;17(5–6): 547–56.

26. Schartner JM, Hagar AR, Van Handel M, et al. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 2005;51(4): 279–85.

27. Kostianovsky AM, Maier LM, Anderson RC, et al. Astrocytic regulation of human monocytic/microglial activation. J Immunol 2008;181(8):5425–32.

28. Roszman TL, Brooks WH. Neural modulation of immune function. J Neuroimmunol 1985;10(1): 59–69.

29. Roszman TL, Brooks WH, Steele C, et al. Pokeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors. Characterization of T helper and B cell function. J Immunol 1985; 134(3):1545–50.

30. Elliott LH, Brooks WH, Roszman TL. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 1984;132(3):1208–15.

31. Brooks WH, Markesbery WR, Gupta GD, et al. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 1978;4(3): 219–24.

32. Palma L, Di Lorenzo N, Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg 1978; 49(6):854–61.

33. Dunn GP, Dunn IF, Curry WT. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 2007;7:12.

34. Safdari H, Hochberg FH, Richardson EP Jr. Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg Neurol 1985;23(3): 221–6.

35. Hussain SF, Heimberger AB. Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther 2005;5(5): 777–90.

36. Gerosa MA, Olivi A, Rosenblum ML, et al. Impaired immunocompetence in patients with malignant gliomas: the possible role of Tg-lymphocyte subpopulations. Neurosurgery 1982;10(5):571–3.

37. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 2006;8(3):234–43.

38. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66(6):3294–302.

39. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188(2):287–96.

40. Camara NO, Sebille F, Lechler RI. Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 2003;33(12):3473–83.

41. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immuno-regulatory cells. J Immunol 2001;167(3):1137–40.

42. Dieckmann D, Bruett CH, Ploettner H, et al. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 2002;196(2):247–53.

43. Liu VC, Wong LY, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007;178(5):2883–92.

44. Zheng Y, Manzotti CN, Liu M, et al. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol 2004;172(5):2778–84.

45. Fecci PE, Sweeney AE, Grossi PM, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006;12(14 Pt 1):4294–305.

46. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006;105(3):430–7.

47. Nitta T, Hishii M, Sato K, et al. Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 1994;649(1-2):122–8.

48. Fontana A, Kristensen F, Dubs R, et al. Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 1982;129(6):2413–9.

49. Sawamura Y, Diserens AC, de Tribolet N. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neurooncol 1990;9(2):125–30.

50. Couldwell WT, Yong VW, Dore-Duffy P, et al. Production of soluble autocrine inhibitory factors by human glioma cell lines. J Neurol Sci 1992;110(1–2):178–85.

51. Dix A, Brooks WH, Roszman TL, et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999;100(1–2):216–32.

52. Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 1989;143(10):3222–9.

53. Fontana A, Hengartner H, de Tribolet N, et al. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 1984;132(4):1837–44.

54. Fontana A, Frei K, Bodmer S, et al. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 1989;143(10):3230–4.

55. Suzumura A, Sawada M, Yamamoto H, et al. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol 1993;151(4):2150–8.

56. Liau L, Fakhrai H, Black K. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol Res 1998;20(8):742–7.

57. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 1996;93(7):2909–14.

58. Yang BC, Lin HK, Hor WS, et al. Mediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by Fas signaling through a protein kinase A-independent pathway. J Immunol 2003;171(8):3947–54.

59. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13(1):84–8.

60. Ichinose M, Masuoka J, Shiraishi T, et al. Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors. Brain Tumor Pathol 2001;18(1):37–42.

61. Hahn HP, Pang M, He J, et al. Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ 2004;11(12):1277–86.

62. Rorive S, Belot N, Decaestecker C, et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 2001;33(3):241–55.

63. Badie B, Schartner J, Prabakaran S, et al. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J Neuroimmunol 2001;120(1-2):19–24.

64. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793–800.

65. Magnus T, Schreiner B, Korn T, et al. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci 2005;25(10):2537–46.

66. Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci 2004;9:411–20.

67. Lesniak MS, Gabikian P, Tyler BM, et al. Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J Neurooncol 2004;70(1):23–8.

68. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22(4):610–6.

69. Kikuchi T, Joki T, Abe T, et al. Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells. J Immunother 1999;22(3):245–50.

70. Jereb B, Petric J, Lamovec J, et al. Intratumor application of human leukocyte interferon-alpha in patients with malignant brain tumors. Am J Clin Oncol 1989;12(1):1–7.

71. Farkkila M, Jaaskelainen J, Kallio M, et al. Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 1994;70(1):138–41.

72. Merchant RE, McVicar DW, Merchant LH, et al. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial. J Neurooncol 1992;12(1):75–83.

73. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001;92(2):420–33.

74. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 2002;94(10):2675–80.

75. Liu Y, Ehtesham M, Samoto K, et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 2002;9(1):9–15.

76. Ren H, Boulikas T, Lundstrom K, et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene—a phase I/II clinical protocol. J Neurooncol 2003;64(1-2):147–54.

77. Ehtesham M, Samoto K, Kabos P, et al. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther 2002;9(11):925–34.

78. Lichtor T, Glick RP, Kim TS, et al. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 1995;83:1038–44.

79. Lichtor T, Glick RP, Tarlock K, et al. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 2002;9(5):464–9.

80. Glick RP, Lichtor T, Panchal R, et al. Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors. J Neurooncol 2003;64(1-2):139–46.

81. Kikuchi T, Joki T, Saitoh S, et al. Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Int J Cancer 1999;80(3):425–30.

82. Benedetti S, Pirola B, Pollo B, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000;6(4):447–50.

83. Ehtesham M, Kabos P, Kabosova A, et al. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002; 62(20):5657–63.

84. Yuan X, Hu J, Belladonna ML, et al. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res 2006;66(5):2630–8.

85. Mizuno M, Yoshida J. Effect of human interferon beta gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells. Cancer Immunol Immunother 1998;47(4):227–32.

86. Natsume A, Mizuno M, Ryuke Y, et al. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 1999;6(9):1626–33.

87. Natsume A, Tsujimura K, Mizuno M, et al. IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 2000; 47(2):117–24.

88. Rhines LD, Sampath P, DiMeco F, et al. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery 2003;52(4):872–9 [discussion: 879–80].

89. Hanes J, Sills A, Zhao Z, et al. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 2001;18(7): 899–906.

90. Hsu W, Lesniak MS, Tyler B, et al. Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. J Neurooncol 2005;74(2):135–40.

91. Puri RK, Leland P, Kreitman RJ, et al. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-*Pseudomonas* exotoxin chimeric protein. Int J Cancer 1994;58(4):574–81.

92. Joshi BH, Leland P, Asher A, et al. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res 2001;61(22):8058–61.

93. Joshi BH, Leland P, Silber J, et al. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-*Pseudomonas* exotoxin fusion protein. Br J Cancer 2002; 86(2):285–91.

94. Rand RW, Kreitman RJ, Patronas N, et al. Intratumoral administration of recombinant circularly permuted interleukin-4-*Pseudomonas* exotoxin in

patients with high-grade glioma. Clin Cancer Res 2000;6(6):2157–65.

95. Weber FW, Floeth F, Asher A, et al. Local convec-tion enhanced delivery of IL4-*Pseudomonas* exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003;88:93–103.

96. Weber F, Asher A, Bucholz R, et al. Safety, tolera-bility, and tumor response of IL4-*Pseudomonas* exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003;64(1–2): 125–37.

97. Kioi M, Kawakami K, Puri RK. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-tar-geted cytotoxin composed of IL-13 antagonist and *Pseudomonas* exotoxin. Clin Cancer Res 2004;10(18 Pt 1):6231–8.

98. Joshi BH, Leland P, Puri RK. Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein. Croat Med J 2003;44(4): 455–62.

99. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001;92(2):168–75.

100. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003;88:105–11.

101. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparen-chymal Study Group. J Clin Oncol 2007;25(7): 837–44.

102. Parney IF, Kunwar S, McDermott M, et al. Neurora-diographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005;102(2):267–75.

103. Kioi M, Seetharam S, Puri RK. Targeting IL-13Ral-pha2-positive cancer with a novel recombinant im-munotoxin composed of a single-chain antibody and mutated *Pseudomonas* exotoxin. Mol Cancer Ther 2008;7(6):1579–87.

104. Vogelbaum MA, Sampson JH, Kunwar S, et al. Convection-enhanced delivery of cintredekin besu-dotox (interleukin-13-PE38QQR) followed by radia-tion therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 2007;61(5): 1031–7 [discussion: 1037–8].

105. Heimbrook DC, Stirdivant SM, Ahern JD, et al. Transforming growth factor alpha-*Pseudomonas* exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. Proc Natl Acad Sci U S A 1990;87(12):4697–701.

106. Phillips PC, Levow C, Catterall M, et al. Transform-ing growth factor-alpha-*Pseudomonas* exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 1994;54(4):1008–15.

107. Sampson JH, Akabani G, Archer GE, et al. Prog-ress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the *Pseudomonas* exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65(1):27–35.

108. Sampath P, Hanes J, DiMeco F, et al. Paracrine immunotherapy with interleukin-2 and local chemo-therapy is synergistic in the treatment of experi-mental brain tumors. Cancer Res 1999;59(9): 2107–14.

109. Hopkins K, Papanastassiou V, Kemshead JT. The treatment of patients with recurrent malig-nant gliomas with intratumoral radioimmunocon-jugates. Recent Results Cancer Res 1996;141: 159–75.

110. Prasad G, Wang H, Hill DL, et al. Recent advances in experimental molecular therapeutics for malig-nant gliomas. Curr Med Chem Anticancer Agents 2004;4(4):347–61.

111. Bourdon MA, Wikstrand CJ, Furthmayr H, et al. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983;43(6):2796–805.

112. Lee Y, Bullard DE, Humphrey PA, et al. Treatment of intracranial human glioma xenografts with ^{131}I-labeled antitenascin monoclonal antibody 81C6. Cancer Res 1988;48(10):2904–10.

113. Lee YS, Bullard DE, Zalutsky MR, et al. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix ^{131}I-radiolabeled murine monoclonal anti-body in a human glioma xenograft model. Cancer Res 1988;48(3):559–66.

114. Zalutsky MR, Moseley RP, Coakham HB, et al. Pharmacokinetics and tumor localization of ^{131}I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989;49(10):2807–13.

115. Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998; 16(6):2202–12.

116. Brown M, Coleman RE, Friedman AH, et al. Intra-thecal ^{131}I-labeled antitenascin monoclonal anti-body 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor

resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996; 2(6):963–72.

117. Riva P, Fraceschi G, Arista A, et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 1997;80(Suppl 12):2733–42.

118. Akabani G, Cokgor I, Coleman RE, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 2000;46(4):947–58.

119. Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006;24(1):115–22.

120. Akabani G, Reardon DA, Coleman RE, et al. Dosimetry and radiographic analysis of ^{131}I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 2005; 46(6):1042–51.

121. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 20(5):1389–97.

122. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000;18(22):3862–72.

123. Reardon DA, Quinn JA, Akabani G, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with ^{131}I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med 2006;47(6):912–8.

124. Kalofonos HP, Pawikowska TR, Hemingway A, et al. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 1989; 30(10):1636–45.

125. Dadparvar S, Krishna L, Miyamoto C, et al. Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer 1994; 73(Suppl 3):884–9.

126. Faillot T, Magdelenat H, Mady E, et al. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 1996;39(3):478–83.

127. Crombet T, Torres O, Neninger E, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 2001;16(1): 93–102.

128. Stragliotto G, Vega F, Stasiecki P, et al. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer 1996;32(4):636–40.

129. Wersall P, Ohlsson I, Biberfeld P, et al. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 1997;44(3):157–64.

130. Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006;5(4):375–9.

131. Brady LW. A new treatment for high grade gliomas of the brain. Bull Mem Acad R Med Belg 1998; 153(5–6):255–61 [discussion: 261–2].

132. Brady LW, Markoe AM, Woo DV, et al. Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study. Front Radiat Ther Oncol 1990;24:151–60 [discussion: 161–5].

133. Brady LW, Miyamoto C, Woo DV, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1992;22(1):225–30.

134. Snelling L, Miyamoto CT, Bender H, et al. Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 1995;14(2):111–4.

135. Jungbluth AA, Stockert E, Huang JH, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 2003;100(2):639–44.

136. Sampson JH, Crotty LE, Lee S, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 2000;97(13):7503–8.

137. Mishima K, Johns TG, Luwor RB, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 2001;61(14):5349–54.

138. Mamot C, Drummond DC, Greiser U, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient

drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003;63(12):3154–61.

139. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65(24):11631–8.

140. Hall WA. Targeted toxin therapy for malignant astrocytoma. Neurosurgery 2000;46(3):544–51 [discussion: 552].

141. Jacobs SK, Wilson SK, Kronblith PL, et al. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg 1986;64(5):743–9.

142. Merchant RE, Grant AJ, Merchant LH, et al. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 1988;62(4):665–71.

143. Merchant RE, Merchant LH, Cook SH, et al. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 1988;23(6):725–32.

144. Barba D, Saris SC, Holder C, et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70(2):175–82.

145. Lillehei KO, Mitchell DH, Johnson SD, et al. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 1991;28(1):16–23.

146. Hayes RL, Koslow M, Hiesiger EM, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995;76(5):840–52.

147. Dillman RO, Duman CM, Schiltz PM, et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 2004;27(5):398–404.

148. Nitta T, Sato K, Okumura K, et al. Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells. J Neurosurg 1990;72(3):476–81.

149. Nitta T, Sato K, Yagita H, et al. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990;335(8686):368–71.

150. Tsurushima H, Lui SQ, Tsuboi K, et al. Induction of human autologous cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme. J Neurosurg 1996;84(2):258–63.

151. Saris SC, Spiess P, Lieberman DM, et al. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 1992;76(3):513–9.

152. Holladay FP, Heitz T, Wood GW. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J Neurosurg 1992;77(5):757–62.

153. Holladay FP, Hetiz T, Chen YL, et al. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 1992;31(3):528–33.

154. Holladay F, Heitz T, Wood GW, et al. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J Neuro oncol 1996;27(2):179–89.

155. Quattrocchi KB, Miller CH, Cush S, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 1999;45(2):141–57.

156. Miescher S, Stoeck M, Whiteside TL, et al. Altered activation pathways in T lymphocytes infiltrating human solid tumors. Transplant Proc 1988;20(2):344–6.

157. Miescher S, Whiteside TL, de Tribolet N, et al. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 1988;68(3):438–48.

158. Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991;12(10):370–4.

159. Prins RM, Graf MR, Merchant RE. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol Immunother 2001;50(6):285–92.

160. Plautz G, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998;89(1):42–51.

161. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000;6(6):2209–18.

162. Cesano A, Visonneau S, Santoli D. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line. Cancer Res 1995;55(1):96–101.

163. Cesano A, Visonneau S, Santoli D. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice. Anticancer Res 1998;18(4A):2289–95.

164. Cesano A, Visonneau S, Pasquini S, et al. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res 1996;56(19):4444–52.

165. Geoerger B, Tang CB, Cesano A, et al. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts. Neuro Oncol 2000;2(2):103–13.

166. Kruse CA, Visonneau S, Kleinschmidt-DeMasters BK, et al. The human leukemic T-cell

line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. Cancer Res 2000;60(20):5731–9.

167. Gomez GG, Read SB, Gerschenson LE, et al. Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. Neuro Oncol 2004;6(2):83–95.

168. Brando C, Mukhopadhyay S, Kovacs E, et al. Receptors and lytic mediators regulating antitumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol 2005;78(2):359–71.

169. Wikstrand CJ, Bigner DD. Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha. J Natl Cancer Inst 1998;90(11):799–801.

170. Lozupone F, Rivoltini L, Luciani F, et al. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 2003;33(2):556–66.

171. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004;22(21):4272–81.

172. Sloan AE, Dansey R, Zamorano L, et al. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 2000;9(6):e9.

173. Ishikawa E, Tsuboi K, Yamamoto T, et al. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 2007;98(8):1226–33.

174. Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 2007;5:67.

175. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223(1):1–15.

176. Siesjö P, Visse E, Sjögren H. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol 1996;19(5):334–45.

177. Liau L, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999;90(6):1115–24.

178. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61(3):842–7.

179. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001;50(7):337–44.

180. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004;27(6):452–9.

181. Kjaergaard J, Wang LX, Kuriyama H, et al. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 2005;103(1):156–64.

182. Yu JS, Lui G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64(14):4973–9.

183. Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003;89(7):1172–9.

184. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004;91(9):1656–62.

185. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11(15):5515–25.

186. Ludewig B, Oschesenbein AF, Odermatt B, et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000;191(5):795–804.

187. Wu AH, Xiao J, Anker L, et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 2006;76(1):23–30.

188. Heimberger AB, Archer GE, Crotty LE, et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 2002;50(1):158–64 [discussion 164–6].

189. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003;9(11):4247–54.

190. Wood GW, Holladay FP, Turner T, et al. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated

lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 2000;48(2):113–20.

191. Liau LM, Jensen ER, Kremen TJ, et al. Tumor immunity within the central nervous system stimulated by recombinant *Listeria monocytogenes* vaccination. Cancer Res 2002;62(8):2287–93.

192. Brockstedt DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 2004;101(38):13832–7.

193. Meyer RG, Britten CM, Siepmann U, et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 2005;54(5):453–67.

194. Yang L, Ng KY, Lillehei KO. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 2003;10(2):138–47.

195. Kuwashima N, Nishimura F, Eguchi J, et al. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 2005; 175(4):2730–40.

196. Okada H, Pollack IF, Lieberman F, et al. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther 2001;12(5):575–95.

197. Yamanaka R, Honma J, Tsuchiya N, et al. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. J Neurooncol 2005;72(2):107–13.

198. Kikuchi T, et al. Antitumor activity of interleukin 12 against interleukin 2-transduced mouse glioma cells. Cancer Lett 1999;135(1):47–51.

199. Parney IF, Petruk KC, Zhang C, et al. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther 1997;8(9): 1073–85.

200. Saleh M, Jonas NK, Wiegmans A, et al. The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer. Gene Ther 2000; 7(20):1715–24.

201. Benedetti S, Bruzzone MG, Pollo B, et al. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res 1999;59(3):645–52.